35 results
SC TO-T/A
EX-99
KNTE
Kinnate Biopharma Inc
19 Mar 24
Third party tender offer statement (amended)
4:44pm
.
The offeror’s estimate of the Disposition Proceeds is based on the offeror’s assessment of the CVR Products together with Kinnate’s independent estimate … or compromise any Tax liability or refund, or consent to any extension or waiver of any limitation period with respect to any claim or assessment for Taxes
SC 14D9
KNTE
Kinnate Biopharma Inc
4 Mar 24
Tender offer solicitation
5:27pm
with Party A, as the Special Committee believed that the terms of Party A’s non-binding indication of interest and the Special Committee’s assessment … . The Special Committee’s and the disinterested and independent members of the Kinnate Board’s assessment of the assets, liabilities and financial
SC TO-T
EX-99
KNTE
Kinnate Biopharma Inc
4 Mar 24
Third party tender offer statement
5:24pm
.
The offeror’s estimate of the Disposition Proceeds is based on the offeror’s assessment of the CVR Products together with Kinnate’s independent estimate … limitation period with respect to any claim or assessment for Taxes;
(n) amend, cancel or terminate any insurance policy naming Kinnate or its subsidiaries
8-K
EX-2.1
KNTE
Kinnate Biopharma Inc
1 Mar 24
Entry into a Material Definitive Agreement
8:50am
assessment or charge of similar kind or nature (including withholding on amounts paid to or by any Person), together with any interest, penalty, addition
8-K
EX-2.1
KNTE
Kinnate Biopharma Inc
16 Feb 24
Entry into a Material Definitive Agreement
9:10am
limitation period with respect to any material claim or assessment for Taxes;
(viii) any Contract to which the Company or its subsidiaries are a party … or waivers to extend, the statutory period of limitations applicable to the collection, assessment or reassessment of any material Taxes or material Tax
8-K
EX-99.1
o0tolb3 hrp50ubr5e
18 Sep 23
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
4:28pm
8-K
EX-99.1
w3obftm8p887ju
17 Apr 23
Results of Operations and Financial Condition
3:15pm
8-K
EX-99.1
14wj76
10 Nov 22
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
4:26pm
8-K
EX-99.1
ykmocdy58vrkfgab6
11 Oct 22
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
4:17pm
S-3ASR
EX-1.2
xile71u0ufjtnk0t eqf
3 Jan 22
Automatic shelf registration
8:51am